The Greater New York Node of the NIDA Clinical Trials Network (CTN), under the shared leadership of Drs. Edward Nunes and John Rotrosen, represents a merger of the Long Island and New York Nodes. Over the past decade we have built a network of collaborating researchers from Columbia University, New York University and The Rockefeller University, and from community-based treatment programs (CTPs) spanning the Nation's largest and most diverse metropolitan area. We have made substantial contributions to the CTN, leading 5 CTN studies, contributing 22 performance sites to CTN clinical trials, providing leadership in the CTN organization at the national level in multiple areas, and implementing numerous studies on the local CTN platform. Our vision for the CTN of the future includes (a) a continued focus on effectiveness research, (b) an additional focus on earlier stage 2 / phase 2 research where CTN resources can be efficiently used, (c) an enhanced research-to-practice model to foster sustainable adoption of innovation, and (d) a platform on which focused- and population- level genetics-, clinical neuroscience-, epidemiology- and services- research can be conducted. We bring to the table the expertise, resources and partners necessary to support this vision. Our research team has complementary strengths in pharmacotherapy, behavioral therapy, co-occurring psychiatric and medical disorders, gender issues, HIV risk reduction and treatment, technology-based treatment, mainstream healthcare settings, clinical neuroscience and genetics. Our CTPs include large public and private hospital-based healthcare systems with focused addiction treatment services (Bellevue, North Shore-LIJ, St.Lukes Roosevelt, and VA NYHHS), to which-we are adding the Albert Einstein system in the Bronx, and SUNY Upstate, the major provider for a large portion of upstate New York, as well as traditional free-standing addictions programs (ARTC, Gracie Square, LESC, Odyssey House, Narco-Freedom, Phoenix House). We continue to engage leaders of very large systems, including the NY State SSA (OASAS) and the NY City Health and Hospitals Corporation, as well as the NeATTG, as members of our Executive Committee so that their input can inform the research agenda and foster adoption.

Public Health Relevance

'Addictions, including nicotine, drugs, and alcohol, represent a major public health problem. Research is needed to translate new basic and therapeutic advances into effective and accessible treatment in our communities, The NIDA Clinical Trials Network, and the Greater New York Node proposed here, seek to fill this gap by engaging researchers and community-based providers collaboratively in treatment research.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-KXH-C (04))
Program Officer
Dobbins, Ronald
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York State Psychiatric Institute
New York
United States
Zip Code
McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531
Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951
Shulman, Matisyahu; Campbell, Aimee; Pavlicova, Martina et al. (2018) Cognitive functioning and treatment outcomes in a randomized controlled trial of internet-delivered drug and alcohol treatment. Am J Addict 27:509-515
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032
Aharonovich, Efrat; Campbell, Aimee N C; Shulman, Matisyahu et al. (2018) Neurocognitive Profiling of Adult Treatment Seekers Enrolled in a Clinical Trial of a Web-delivered Intervention for Substance Use Disorders. J Addict Med 12:99-106
Trivedi, Madhukar H; Greer, Tracy L; Rethorst, Chad D et al. (2017) Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. J Clin Psychiatry 78:1075-1082
Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80
Blanco, Carlos; Campbell, Aimee N; Wall, Melanie M et al. (2017) Toward National Estimates of Effectiveness of Treatment for Substance Use. J Clin Psychiatry 78:e64-e70
Worley, Matthew J; Heinzerling, Keith G; Shoptaw, Steven et al. (2017) Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. Addiction 112:1202-1209
Chang, Kun-Chia; Wang, Jung-Der; Saxon, Andrew et al. (2017) Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan. Int J Drug Policy 43:1-6

Showing the most recent 10 out of 131 publications